Literature DB >> 28570428

Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: A Multicenter Analysis.

Kang Chao1, Xueding Wang, Qian Cao, Jiaming Qian, Kaichun Wu, Xia Zhu, Hong Yang, Jie Liang, Lang Lin, Zicheng Huang, Yu Zhang, Yibiao Huang, Yinghao Sun, Xianmin Xue, Min Huang, Pinjin Hu, Ping Lan, Xiang Gao.   

Abstract

BACKGROUND: NUDT15 c.415C>T was a novel genetic marker confirmed in our center for thiopurine-induced leukopenia in Chinese inflammatory bowel disease (IBD). For validation, a large cohort study is needed. Meanwhile, the newly discovered NUDT15 coding variants (c.36_37insGGAGTC and c.52 G>A) have not been studied in patients with IBD. We aimed to further confirm the influence of 3 NUDT15 variants (c.415C>T, c.36_37insGGAGTC, and c.52G>A) on thiopurine-induced leukopenia in Chinese patients with IBD.
METHODS: Patients prescribed on thiopurines for at least 2 weeks were recruited from 4 tertiary hospitals. Clinical data were collected. NUDT15 genotypes were determined with polymerase chain reaction-RFLP and sequencing. The interactions between variants and leukopenia were analyzed.
RESULTS: A total of 732 patients were included, 177 (24.3%) of whom developed leukopenia. There were strong associations of NUDT15 c.415C>T, c.36_37insGGAGTC, and c.52G>A with thiopurine-induced leukopenia (P = 1.81 × 10, P = 4.74 × 10 and P = 0.04, respectively), whereas there was no relevance for thiopurine S-methyltransferase genotypes (P = 0.25). The predictive sensitivity of NUDT15 c.415C>T was 49.2%, whereas it increased to 55.4% when combined analysis with c.36_37insGGAGTC and c.52G>A. Notably, not only the homozygotes with NUDT15 c.415C>T but also the heterozygotes both carrying c.415C>T and c.52G>A developed early leukopenia. The median dosage for NUDT15 c.415C>T carriers was significantly lower than that for wild-type (P < 0.001).
CONCLUSIONS: We confirmed that NUDT15 c.415C>T, c.36_37insGGAGTC, and c.52G>A variants were risk factors for thiopurine-induced leukopenia. Combined detection of the 3 variants could increase the predictive sensitivity of thiopurine-induced leukopenia and help to distinguish early leukopenia in heterozygote of c.415C>T in Chinese patients with IBD. Treatment monitoring by NUDT15 variants may be promising in individualized therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28570428     DOI: 10.1097/MIB.0000000000001148

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  23 in total

1.  Therapeutic drug monitoring in inflammatory bowel disease: too little too early?-comments on the American Gastroenterology Association Guideline.

Authors:  Heidi Y Su; Mark G Ward; Miles P Sparrow
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-19

2.  High-resolution melt analysis enables simple genotyping of complicated polymorphisms of codon 18 rendering the NUDT15 diplotype.

Authors:  Yoichi Kakuta; Yasuhiro Izumiyama; Daisuke Okamoto; Takeru Nakano; Ryo Ichikawa; Takeo Naito; Rintaro Moroi; Masatake Kuroha; Yoshitake Kanazawa; Tomoya Kimura; Hisashi Shiga; Hisaaki Kudo; Naoko Minegishi; Yosuke Kawai; Katsushi Tokunaga; Masao Nagasaki; Yoshitaka Kinouchi; Yasuo Suzuki; Atsushi Masasmune
Journal:  J Gastroenterol       Date:  2019-10-22       Impact factor: 7.527

3.  Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms.

Authors:  Shinichi Tsujimoto; Tomoo Osumi; Meri Uchiyama; Ryota Shirai; Takaya Moriyama; Rina Nishii; Yuji Yamada; Ko Kudo; Masahiro Sekiguchi; Yuki Arakawa; Masanori Yoshida; Toru Uchiyama; Kiminori Terui; Shuichi Ito; Katsuyoshi Koh; Junko Takita; Etsuro Ito; Daisuke Tomizawa; Atsushi Manabe; Nobutaka Kiyokawa; Jun J Yang; Motohiro Kato
Journal:  Leukemia       Date:  2018-07-02       Impact factor: 11.528

4.  Genetic Polymorphisms of Drug-Metabolizing Enzymes Involved in 6-Mercaptopurine-Induced Myelosuppression in Thai Pediatric Acute Lymphoblastic Leukemia Patients.

Authors:  Kanyarat Khaeso; Nontaya Nakkam; Patcharee Komwilaisak; Piyathida Wongmast; Su-On Chainansamit; Areerat Dornsena; Sirimas Kanjanawart; Suda Vannaprasaht; Wichittra Tassaneeyakul
Journal:  J Pediatr Genet       Date:  2020-09-08

5.  The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.

Authors:  Guiqiang Wang; Atsushi Tanaka; Hong Zhao; Jidong Jia; Xiong Ma; Kenichi Harada; Fu-Sheng Wang; Lai Wei; Qixia Wang; Ying Sun; Yuan Hong; Huiying Rao; Cumali Efe; George Lau; Diana Payawal; Rino Gani; Keith Lindor; Wasim Jafri; Masao Omata; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-05-04       Impact factor: 6.047

Review 6.  Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.

Authors:  Ji Young Chang; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2019-07-09       Impact factor: 3.487

7.  NUDT15 Genetic Variants in Chinese Han, Uighur, Kirghiz, and Dai Nationalities.

Authors:  Fang Zhang; Gulbanur Amat; Yanjing Tang; Ru Chen; Xin Tian; Wenting Hu; Changcheng Chen; Shuhong Shen; Yangyang Xie
Journal:  Front Pediatr       Date:  2022-04-14       Impact factor: 3.569

8.  A direct sequencing assay for pharmacogenetic testing of thiopurine-intolerant NUDT15 alleles in an Asian population.

Authors:  Kok-Siong Poon; Izz Irfan B Imran; Silvester Kheng-Han Chew; Patrice Tan; Karen Mei-Ling Tan
Journal:  BMC Res Notes       Date:  2022-04-25

9.  Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease.

Authors:  Hong-Hui Wang; Ying He; Hong-Xian Wang; Cheng-Ling Liao; Yu Peng; Li-Jian Tao; Wei Zhang; Hui-Xiang Yang
Journal:  World J Gastroenterol       Date:  2018-02-28       Impact factor: 5.742

Review 10.  Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.

Authors:  Yoichi Kakuta; Yoshitaka Kinouchi; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2017-11-30       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.